

Statutory Financial Report.

**St Vincent's Institute
Financial Statements for the
Year Ended 31 December 2015**

CONTENTS

	Page
Directors' Report.....	1
Financial Statements.....	8
Directors' Declaration.....	26
Independent Audit Report.....	27

Directors' Report

Your Directors present their report on the company for the financial year ended 31 December 2015.

Directors

The names of each person who has been a director during the year and to the date of this report are:

Ms Susan M Alberti	Mr Ben Fielding (resigned 9/10/15)
Dr Richard Fox	Prof Mark Hargreaves (appointed 15/02/16)
Mr Paul Holyoake	Ms Karen Inge
Prof Thomas WH Kay	Mr John MacFarlane
Mr Anthony Mancini (resigned 01/11/15)	Mr Stephen Marks
Dr Virginia McNamee	Ms Susan O'Neill (appointed 15/02/16)
Dr Patricia O'Rourke	Mr Peter Riley
Mr Gregory J Robinson (resigned 20/3/15)	Ms Brenda M Shanahan
Prof Stephen Smith (resigned 24/08/15)	Dr Marcus Tierney (appointed 31/08/15)
Mr Michael Wachtel (appointed 10/11/15)	

Directors listed above have been in office since the start of the financial year to the date of this report unless otherwise stated.

Principal Activities

The principal activity of the company during the financial year was medical research.

Objectives

St Vincent's Institute of Medical Research (SVI) is the third oldest independent research institute in Melbourne. Since its inception, SVI has played a leading role in one of Australia's most successful international endeavors – medical research. We carry out biomedical research into common diseases of the community, including: type 1 diabetes, obesity and type 2 diabetes, cardiovascular disease, bone diseases including arthritis and osteoporosis, cancer and Alzheimer's disease.

Our mission is to carry out the highest quality laboratory-based biomedical research in order to make discoveries that will improve the health of the community by preventing or better treating common diseases that cause premature death or reduced quality of life.

Our vision is to be a well-resourced environment recognised and valued by researchers, funding bodies and the community as having a critical mass of excellent, innovative and highly motivated scientists capable of addressing major health questions.

Our values include excellence, passion, creativity, collaboration, individual drive, integrity and questioning of dogma.

We have set out the following strategies towards achieving our mission:

1. Build a financially strong organisation

We rely on grants from government, foundations and charities to financially support our research. Approximately 50% of our funding is through competitive research grants awarded by State and Federal government. As SVI would like to be more independent of government funding, philanthropy is critical to our success especially to support young investigators who in some cases do not as yet have the track record to obtain independent funding and also to provide additional seed funding for research. We are also developing new sources of income including commercial research contracts through collaboration with hospitals, universities and industry. We consistently evaluate opportunities to improve efficiencies in order to restrain operational support costs and remain cognizant of the limited government infrastructure funding.

2. Stimulate scientific excellence and cultivate a strong internal culture

Expanding our laboratory-based research by recruiting, developing and retaining excellent scientists and providing them with top facilities and equipment is critical in achieving our aim to produce high quality and high impact publications describing new findings of our research. The quality of our publications is ranked with the best Australian Medical Research Institutes.

We create an intellectually stimulating environment that is sought out by and nurtures the best scientists and fully meets the needs of our existing staff, enabling them to be internationally competitive.

We promote a strong internal culture with an emphasis on research integrity and ethics as outlined in the Australian Code for the Responsible Conduct of Research. This also extends to complying with laws and social and ethical behavioural standards.

We take advantage of technological developments to better place researchers to achieve research excellence. We offer advanced platform technologies such as our Flow Cytometry Facility with premier support service for cell sorting, analysis and imaging. Imaging modalities such as our computed tomography (CT) have become an essential tool for research, particularly in bone biology, tumour metastasis, and body composition studies. SVI also manages the Victorian Consortium for Cell Therapies (VCCT) Biological Isolator Facility, which was established by the VCCT to facilitate the clinical development of human cell-based therapies.

The HMSTrust Biobank at SVI was officially launched in September 2015 and will enable vital medical research, accelerating the application of new discoveries to patient care. It will allow the storage and collection of human blood and tissue samples. These samples can help researchers confirm or clarify results in human tissues, which may then lead to new treatments.

3. Positively impact health care and build productive relationships

Our aim is for all SVI research groups to have demonstrable clinical and industry collaborations. We create programs that are the best in the country and internationally highly competitive – with a focus on our lead areas of diabetes, structural biology and bone disease. We develop cross-disciplinary groups to address major health issues, such as the obesity epidemic, and promote collaboration within the Institute.

SVI, in collaboration with St Vincent's Hospital, has come to the fore in Australia as one of the leading centres for the treatment of type 1 diabetes. The Hospital and SVI, alongside NSW's Westmead Hospital and SA's Royal Adelaide Hospital host a Nationally Funded Centre for the transplantation of insulin-producing islet cells to treat type 1 diabetes. The program delivers hope to people with unstable type 1 diabetes causing life-threatening hypoglycaemia (very low blood glucose) that cannot be corrected with insulin. Islet cell transplantation is extremely specialised and complex procedure and only a few hospitals world-wide can provide this type of treatment. The Centre makes islet transplantation for people with type 1 diabetes an integrated part of Australia's health system, and showcases the power of cooperation between states to provide best care for people with unstable type 1 diabetes.

We plan to achieve greater impact through quality growth and in April 2015, the operations of O'Brien Institute (OBI) were merged with SVI. OBI's research focuses on reconstructive surgery, including tissue engineering, vascular biology and more recently on lymphatics applied to some of the problems encountered after treatment for cancer.

In tune with our aspirations of promoting research collaboration, SVI is one of the founding partners of the Aikenhead Centre for Medical Discovery (ACMD) to support the creation of a biomedical engineering research and education hub in Victoria. The ACMD will drive innovation and accelerate the commercialisation of new treatments for chronic disease, including bionic devices to replace organs, tissue-engineered cells to cure disease, and targeted drug-delivery systems to provide more effective treatments.

Information on Directors

Ms Brenda M Shanahan	Chairperson
Qualifications	BEd BCom
Experience	Board member since May 1996, Chair since 2005, Director of several public companies.
Ms Susan M Alberti	Director
Qualifications	Hon LLD
Experience	Board member since April 2003, Chair of St Vincent's Institute Foundation, Former President Juvenile Diabetes Research Foundation Australia.
Dr Richard Fox	Director
Qualifications	MB, BS, FRCP
Experience	Board member since September 2014, former Director of Research, SVHM
Prof Mark Hargreaves	Director
Qualifications	BSc (Physiology), MA (Exercise Physiology), PhD (Physiology)
Experience	Board member since February 2016, Dean of the Faculty of Medicine, Dentistry & Health Sciences at the University of Melbourne
Mr Paul Holyoake	Director
Qualifications	BEngMech (Hons), MEngSci
Experience	Board member since May 2006
Special Responsibilities	Member of the Audit & Finance committee.
Ms Karen Inge	Director
Qualifications	BSc, Dip. Diet, APD, FSDA, FSMA
Experience	Board member since July 2014, Practising Dietician, Dir. Institute of Health and Fitness
Prof Thomas WH Kay	Director
Qualifications	BMedSc, MBBS PhD Melb, FRACP, FRCPA
Experience	Board member since April 2003, Executive Director of St Vincent's Institute of Medical Research.
Special Responsibilities	Member of the Audit & Finance committee

Mr John (JT) MacFarlane	Director
Qualifications	MComm
Experience	Board member since July 2008, Executive Chairman and Chief Country Officer, Deutsche Bank Group, Australia & New Zealand.
Mr Stephen Marks	Director
Qualifications	FCA
Experience	Board member since November 2013, chartered accountant. Board Chair Chisholm Institute
Special Responsibilities	Member of the Audit & Finance committee
Dr Virginia McNamee	Director
Qualifications	MB, BS (Hons), PhD Melb, Grad Dip Arts
Experience	Board member since December 2014, Director Melbourne University Veterinary Hospital.
Ms Susan O'Neill	Director
Qualifications	BSc (Nursing), MSc (Nursing)
Experience	Board member since February 2016, CEO St Vincent's Hospital Melbourne
Ms Patricia O'Rourke	Director
Qualifications	Grad Dip App Sci (Nursing), GAICD
Experience	Board member since July 2013, CEO St Vincent's Health Melbourne.
Mr Peter Riley	Director
Qualifications	BBus, CPA FICA, FTIA
Experience	Board member since December 2014, former partner Pitcher Partners.
Dr Marcus Tierney	Director
Qualifications	PhD(Med) BSc (Hons)
Experience	Board member since August 2015, Taxation Partner at PricewaterhouseCoopers in Melbourne, previously a member of the board of the O'Brien Institute.
Mr Michael Wachtel	Director
Qualifications	BComm LLB; LLM (LSE)
Experience	Board member since November 2015, previously Chairman of Ernst & Young (Asia Pacific), current Board Member of the Australian Centre for the Moving Image (ACMI) appointed by the Victorian Government.

Meetings of directors

During the financial year, 12 meetings of directors (including committees) were held. Attendees were:

	Board		Audit & Finance Committee	
	<i>Number eligible to attend</i>	<i>Number attended</i>	<i>Number eligible to attend</i>	<i>Number attended</i>
Alberti, SM	6	3	n/a	n/a
Fielding, B	6	5	n/a	n/a
Fox, R	6	6	n/a	n/a
Holyoake, P	6	6	6	6
Inge, K	6	5	n/a	n/a
Kay, TWH	6	6	6	6
MacFarlane, JT	6	6	n/a	n/a
Marks, S	6	6	6	6
Mancini, A	5	5	n/a	n/a
McNamee, V	6	3	n/a	n/a
O'Rourke, P	6	6	n/a	n/a
Riley, P	6	6	n/a	n/a
Shanahan, BM	6	6	n/a	n/a
Smith, S	5	2	n/a	n/a
Tierney, M	2	2	n/a	n/a
Wachtel, M	1	0	n/a	n/a

The entity is incorporated under the Corporations Act 2001 and is an entity limited by guarantee. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$100 each towards meeting any outstanding obligations of the entity. At 31 December 2015 the collective liability of the members was \$300 (2014: \$300).

Auditor's Independence Declaration


The lead auditor's independence declaration for the year ended 31 December 2015 has been received and can be found on page 7 of the financial statements.

Signed in accordance with a resolution of the Board of Directors.



Director

BM Shanahan



Director

TWH Kay

Dated this 23rd day of March 2016, Melbourne, Australia

AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 60-40 OF THE AUSTRALIAN CHARITIES AND NOT-FOR-PROFITS COMMISSION ACT 2012 TO THE MEMBERS OF ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH

I declare that, to the best of my knowledge and belief during the year ended 31 December 2015 there have been:

- no contraventions of the auditor independence requirements as set out in the *Australian Charities and Not-for-Profits Commission Act 2012* in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.



William Buck Audit (VIC) Pty Ltd
ABN 59 116 151 136



A.P. Marks
Director

Dated this 23rd day of March, 2016

**CHARTERED ACCOUNTANTS
& ADVISORS**

Melbourne Office
Level 20, 181 William Street
Melbourne VIC 3000

Hawthorn Office
Level 1, 465 Auburn Road
Hawthorn East VIC 3123

PO Box 185, Toorak VIC 3142
Telephone: +61 3 9824 8555
williambuck.com

Financial Statements

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 31 December 2015

	<u>Note</u>	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Revenue	3	14,927,220	15,515,727
Other income	3	5,854,164	4,432,485
Total revenue		<u>20,781,384</u>	<u>19,948,212</u>
Consumables and general research expenses		(3,853,706)	(3,470,962)
Employee benefits expense		(11,592,018)	(11,747,813)
Depreciation and amortisation		(2,309,329)	(2,227,706)
Administration expenses		(1,627,519)	(1,597,700)
Transfers to collaborators		(1,959,620)	(2,135,139)
Total expenses	4	<u>(21,342,192)</u>	<u>(21,179,320)</u>
Surplus (Deficit) for the year		<u>(560,808)</u>	<u>(1,231,108)</u>
Other comprehensive income:			
Transfer of retained surplus from the O'Brien Institute	2	2,783,199	-
Net gain (loss) on revaluation of financial assets	12	(290,955)	54,464
Total comprehensive income for the year		<u>1,931,436</u>	<u>(1,176,644)</u>
Total Comprehensive income attributable to members of the entity		<u>1,931,436</u>	<u>(1,176,644)</u>

The accompanying notes form part of these financial statements

Statement of Financial Position**As at 31 December 2015**

	Note	2015 (\$)	2014 (\$)
Cash and cash equivalents	5	10,955,053	6,635,128
Trade and other receivables	6	1,788,699	4,028,626
Other assets	8	84,551	88,220
Total current assets		<u>12,828,303</u>	<u>10,751,974</u>
Trade and other receivables	6	250,000	250,000
Financial assets	7	11,422,798	9,630,871
Property, plant & equipment	9	5,374,200	6,865,031
Total non-current assets		<u>17,046,998</u>	<u>16,745,902</u>
TOTAL ASSETS		<u>29,875,301</u>	<u>27,497,876</u>
Trade and other payables	10	3,502,052	3,247,937
Short-term provisions	11	1,658,409	1,463,558
Funds held in trust for NSRL accrued leave	15	138,280	138,280
Total current liabilities		<u>5,298,741</u>	<u>4,849,775</u>
Long-term provisions	11	85,746	88,722
Total non-current liabilities		<u>85,746</u>	<u>88,722</u>
TOTAL LIABILITIES		<u>5,384,487</u>	<u>4,938,497</u>
NET ASSETS		<u>24,490,815</u>	<u>22,559,379</u>
Retained surplus		23,999,116	21,776,725
Reserves	12	491,699	782,654
TOTAL EQUITY		<u>24,490,815</u>	<u>22,559,379</u>

The accompanying notes form part of these financial statements

Statement of Changes in Equity

For the year ended 31 December 2015

	Retained Surplus (\$)	Financial Asset Reserve (\$)	Total (\$)
Balance at 1 January 2014	23,007,833	728,191	23,736,024
Total comprehensive income for the year:			
Deficit attributed to members	(1,231,108)	(1)	(1,231,109)
Other comprehensive income for the year:			
Net gain on revaluation of assets	-	54,464	54,464
Balance at 31 December 2014	21,776,725	782,654	22,559,379
Total comprehensive income for the year:			
Deficit attributed to members	(560,808)	-	(560,808)
Other comprehensive income for the year:			
Transfer of retained surplus from the O'Brien Institute	2,783,199	-	2,783,199
Net loss on revaluation of assets	-	(290,955)	(290,955)
Balance at 31 December 2015	23,999,116	491,699	24,490,815

The accompanying notes form part of these financial statements

Statement of Cash Flows**For the year ended 31 December 2015**

	Note	2015 Inflows (Outflows) \$	2014 Inflows (Outflows) \$
Cash flow from operating activities:			
Grants received		17,540,876	13,800,499
Payments to suppliers and employees		(19,247,162)	(19,019,360)
Donations, legacies and bequests		3,075,455	1,947,885
Other revenue		1,622,240	1,482,114
Interest received		248,553	448,207
Dividends received		705,296	712,680
Net cash generated from (used in) operating activities		<u>3,945,258</u>	<u>(627,975)</u>
Cash flow from investing activities:			
Cash acquired from transfer of OBI	2	2,754,415	-
Payment for property, plant, equipment, fittings, and motor vehicles		(320,977)	(1,268,331)
Payments for available for sale investments		<u>(2,082,882)</u>	<u>(3,671,412)</u>
Net cash generated from (used in) investing activities		<u>350,556</u>	<u>(4,939,743)</u>
Net increase (decrease) in cash		4,295,814	(5,567,718)
Effect of exchange rate differences on cash		24,111	-
Cash and cash equivalents at the beginning of the year		6,635,128	12,202,846
Cash and cash equivalents at the end of the year	5	<u>10,955,053</u>	<u>6,635,128</u>

The accompanying notes form part of these financial statements

Notes to the Financial Statements for the year ended 31 December 2015

The financial statements are for St Vincent's Institute of Medical Research as an individual entity, incorporated and domiciled in Australia. St Vincent's Institute of Medical Research is a company limited by guarantee.

Note 1: Summary of Significant Accounting Policies

New, revised or amending Accounting Standards and Interpretations adopted.

St Vincent's Institute of Medical Research has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Basis of preparation

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements of the Australian Accounting Standards Board and the Australian Charities and Not-For-Profits Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

The financial statements were authorised for issue on the 23rd March 2016 by the directors of the company.

Accounting Policies

(a) Revenue

Grant revenue is recognised in the statement of profit or loss and other comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.

If conditions are attached to the grant, which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Donations and bequests are recognised as revenue when received.

Interest revenue is recognised using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

All revenue is stated net of the amount of goods and services tax (GST).

(b) Property, plant and equipment

Each class of property, plant and equipment is carried at cost or fair value as indicated, less, where applicable, accumulated depreciation and impairment losses.

(i) Leasehold improvements

Existing Building: In 2002 and 2003 the company extended and refurbished the existing building, which is leased by the company from the Mary Aikenhead Ministries Limited. The building lease arrangement provides the company with both a future economic benefit and control over that future economic benefit. The cost of the leasehold improvement has been capitalised and appears in the statement of financial position.

Bio-resources Centre: In 2005 the company paid \$825,574 towards the building of an additional research facility on the St Vincent's Hospital Melbourne campus. The hospital will manage the facility and the company's investment gives long-term entitlement to access the facility. The entitlement provides the company with an economic benefit and control over that future economic benefit. The cost of the leasehold improvement has been capitalised and appears in the statement of financial position.

Micro-isolator facility: In 2013 the company signed a lease to occupy the 3rd floor of the O'Brien Institute, located on the St Vincent's Hospital Melbourne campus. The entitlement provides the company with an economic benefit and control over that future economic benefit. The leasehold improvement, which was completed in December 2013 at a cost of \$360,398, has been capitalised and appears in the statement of financial position. The facility commenced operations in 2014.

St. Vincent's Chronic Diseases Bio-bank facility: In 2014 the company commenced construction of the Bio-bank, at a cost of \$511,482, which has been capitalised. The Bio-bank is located on the leased premises of the National Serology Reference Laboratory - NSRL (refer Note 1 (I)). The intention of the Facility is to prospectively collect, store and distribute appropriate samples for clinical and diagnostic research and collaboration in the areas of diabetes and its complications, immunology, and autoimmunity. This resource will be a valuable tool for researchers to store their samples from clinics, surgery, and clinical trials to draw on for future research studies. The NSRL and Bio-bank building lease arrangement provides the company with both a future economic benefit and control over that future economic benefit. The cost of the leasehold improvement has been capitalised and appears in the statement of financial position. The facility commenced operations in 2015.

(ii) Plant and equipment

Plant and equipment are measured on the cost basis and therefore carried at cost less accumulated depreciation and any accumulated impairment losses. In the event the carrying amount of plant and equipment is greater than its estimated recoverable amount, the carrying amount is written down immediately to its estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to the revalued asset.

The company does not apply the recoverable amount valuation process. However prudent depreciation rates have been selected to overcome the difficulty in determining the recoverable amount. The company's plant, equipment and fixtures are generally fully depreciated well before the end of the assets useful life and leasehold improvement is depreciated in line with the duration of the lease.

Plant and equipment that have been contributed at no cost, or for nominal cost, are valued and recognised at the fair value of the asset at the date it is acquired.

Subsequent costs are included in the assets carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably.

All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

(iii) Depreciation

The depreciable amount of all fixed assets including leasehold improvements are depreciated on a straight line basis over the assets useful life to the company commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements. Depreciation is recognised in profit or loss.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Leasehold improvements	7%
Plant and equipment	20 – 33%
Motor vehicles	33%

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in profit or loss. When revalued assets are sold, amounts included in the revaluation surplus relating to that asset are transferred to retained earnings.

(c) Financial instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified 'at fair value through profit or loss' in which case transaction costs are expensed to profit or loss immediately.

Classification and subsequent measurement

Finance instruments are subsequently measured at either fair value, amortised cost using the effective interest rate method or cost. *Fair value* represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Amortised cost is calculated as:

- (i) the amount at which the financial asset or financial liability is measured at initial recognition;
- (ii) less principal repayments;
- (iii) plus or minus the cumulative amortisation of the difference, if any, between the amount initially recognised and the maturity amount calculated using the *effective interest method*; and
- (iv) less any reduction for impairment.

The *effective interest method* is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense in item in profit or loss.

(i) Financial assets at fair value through profit or loss

Financial assets are classified at 'fair value through profit or loss' when they are held for trading for the purpose of short-term profit taking, or where they are derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying value being included in profit or loss.

(ii) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.

(iii) Held-to-maturity investments

Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the company's intention to hold these investments to maturity. They are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.

(iv) Available-for-sale investments

Available-for-sale financial assets are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature, or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments.

They are subsequently measured at fair value with any remeasurements other than impairment losses and foreign exchange gains and losses recognised in other comprehensive income. When the financial asset is derecognised, the cumulative gain or loss pertaining to that asset previously recognised in other comprehensive income is reclassified into profit and loss.

Available-for-sale financial assets are classified as non-current assets when they are expected to be sold more than 12 months after the end of the reporting period. All other available-for-sale financial assets are classified as current assets.

(v) Financial liabilities

Non-derivative financial liabilities other than financial guarantees are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial liability is derecognised.

Fair Value

Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arms length transactions, reference to similar instruments and option pricing models.

Impairment

At the end of each reporting period, the company assesses whether there is objective evidence that a financial asset has been impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence that impairment as a result of one or more events (a "loss event") has occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to constitute a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified to profit or loss at this point.

In the case of financial assets carried at amortised cost, loss events may include: indications that the debtors or a group of debtors are experiencing significant financial difficulty, default or delinquency in interest or principal payments; indications that they will enter bankruptcy or any other financial reorganisation; and changes in arrears or economic conditions that correlate with defaults.

For financial assets carried at amortised cost (including loans and receivables), a separate allowance account is used to reduce the carrying amount of financial assets impaired by credit losses. After having taken all possible measures of recovery, if management establishes that the carrying amount cannot be recovered by any means, at that point the written-off amounts are charged to the allowance account or the carrying amount of impaired financial assets is reduced directly if no impairment amount was previously recognised in the allowance accounts.

When the terms of financial assets that would otherwise have been past due or impaired have been renegotiated, the company recognises the impairment for such financial assets by taking into account the original terms as if

the terms have not been renegotiated so that the loss events that have occurred are duly considered.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised when the related obligations are discharged or cancelled or have expired. The difference between the carrying amount of the financial liability, which is extinguished or transferred to another party, and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

(d) Impairment of assets

At the end each reporting period, the entity assesses whether there is any indication that an asset may be impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, to the asset's carrying amount. Any excess of the assets carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard (eg in accordance with the revaluation model in AASB 116). Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other Standard.

Where it is not possible to estimate the recoverable amount of an individual asset, the entity estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

(e) Foreign currency transactions and balances

Functional and presentation currency

The functional currency of the company is measured using the currency of the primary economic environment in which the company operates. The financial statements are presented in Australian dollars, which is the company's functional and presentation currency.

Transaction and balances

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items are recognised in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge.

Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in profit or loss.

(f) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts.

(g) Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period, which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(h) Provisions

Provisions are recognised when the entity has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of the reporting period.

(i) Employee benefits

Provision is made for the company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits are measured at the amounts expected to be paid when the liability is settled. If the benefit is not expected to be settled within twelve months it is accounted for as an other long-term liability.

In determining other long-term liabilities, consideration is given to employee wage increases and the probability that the employee may not satisfy vesting requirements. Those cash flows are discounted using market yields on national government bonds with terms to maturity that match the expected timing of cash flows.

Contributions are made by the entity to an employee superannuation fund and are charged as expenses when incurred.

(j) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing and financing activities, which are recoverable from or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

(k) Income tax

The company is granted exemption from income tax under Subdivision 50 of the Income Tax Assessment Act 1997 because of the charitable nature of the business.

(l) National Serology Reference Laboratory

The company is the host company for the National Serology Reference Laboratory (NSRL). In this role the company provides contract administration services to the 31 employees. The NSRL financial reporting is separate from the company and reported on a 30 June financial year basis to the Commonwealth Government. The current host agreement expires on 30 June 2016 and SVI is in discussions with the government in regards to renewal of the agreement.

(m) Comparative figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(n) Critical accounting estimates and judgments

The directors evaluate estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

(o) Key judgements*Available-for-sale investments*

The company maintains a portfolio of securities with a carrying value of \$11,422,798 at the end of the reporting period. During the 2015 year the combined value of financial investment has increased by \$1,791,926, which included additional contributions to the securities portfolio as well as dividend and profit on sale reinvestment, offset by a reduction in market value of the portfolio (\$290,955). There is no impairment of investments to be recognised for 2015. The Audit and Finance Committee, in consultation with the company's external financial managers, carefully monitor the value of the investments during the year. Reports are regularly given to the directors, who review the value at year-end to determine whether such investments will be considered impaired.

(p) Economic dependence

St Vincent's Institute of Medical Research is dependent on State and Federal government funding for 50% of its revenue used to operate the business. At the date of this report the board of directors has no reason to believe the governments will not continue to support St Vincent's Institute of Medical Research.

Note 2: Acquisition of O'Brien Institute

On April 30 2015, the operations of O'Brien Institute (OBI) were merged with St. Vincent's Institute of Medical Research (SVI) and the net assets of OBI as at that date were transferred to SVI for nil consideration. OBI's research focuses on reconstructive surgery, including tissue engineering, vascular biology and more recently on lymphatics applied to some of the problems encountered after treatment for cancer.

The merger has been accounted for as a transaction between entities under common control in which the assets and liabilities of OBI were transferred to the books of SVI at carrying values as at merger date and the residual was recognised as an equity contribution.

The assets and liabilities transferred to SVI as at merger date were:

O'Brien Institute Net Assets as at merger date	30 April 2015
	(\$)
Cash and cash equivalents	2,754,415
Trade and other receivables	627,032
Other assets	2,569
Total current assets	<u>3,384,016</u>
Property, plant & equipment	498,371
Total non-current assets	<u>498,371</u>
TOTAL ASSETS	<u>3,882,387</u>
Trade and other payables	803,378
Short-term provisions	193,234
Total current liabilities	<u>996,612</u>
Long-term provisions	102,576
Total non-current liabilities	<u>102,576</u>
TOTAL LIABILITIES	<u>1,099,188</u>
NET ASSETS	<u>2,783,199</u>

The operating results of OBI are included in SVI's financial statements from the date of acquisition.

Note 3: Revenue and Other Income

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Income from research activities:		
Government grants for direct research		
<i>Commonwealth Government</i>		
National Health and Medical Research Council	7,223,716	8,164,195
Australian Research Council	727,595	651,811
Government grants for operational support		
<i>Commonwealth Government</i>		
National Health and Medical Research Council (Independent Research Institutes Infrastructure Support Scheme)	1,307,987	1,586,253
<i>Victorian State Government</i>		
Department of Health and Human Services (Operational Infrastructure Support Program)	1,537,917	1,483,492
Other research grants	4,130,005	3,629,976
Total income from research activities	<u>14,927,220</u>	<u>15,515,727</u>
Other income:		
Legacies, bequests, donations	3,095,063	1,965,474
Dividends/share trading from other corporations	813,313	712,680
Interest from other corporations	237,878	396,675
Contract services	1,029,803	786,952
Royalty	40,828	26,377
Sale of asset	-	18,727
Other	637,279	525,600
Total other income	<u>5,854,164</u>	<u>4,432,485</u>
Total revenues	<u>20,781,384</u>	<u>19,948,212</u>

Note 4: Expenses

The following expenditure was incurred in determining the deficit for the year:

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Expenses:		
Direct research costs	12,739,309	12,646,528
Operational support	4,333,934	4,169,947
	<u>17,073,243</u>	<u>16,816,475</u>
Transfer of funds to external, joint collaborators	1,959,620	2,135,139
Depreciation and amortisation of non-current assets	2,309,329	2,227,706
Total expenses	<u>21,342,192</u>	<u>21,179,320</u>

Note 5: Cash and Cash Equivalents

	<u>Note</u>	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Cash at bank and on hand		3,055,053	635,128
Term deposits		7,900,000	6,000,000
Total cash and cash equivalents	17	<u>10,955,053</u>	<u>6,635,128</u>

Note 6: Trade and Other Receivables

	<u>Note</u>	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Current			
Grants and reimbursements		1,788,699	4,028,626
Provision for impairment of receivables		-	-
		<u>1,788,699</u>	<u>4,028,626</u>
Non-current			
St. Vincent's Hospital - imprest advance		250,000	250,000
		<u>250,000</u>	<u>250,000</u>
Financial assets classified as loans and receivables			
Trade and other receivables:			
Total current		1,788,699	4,028,626
Total non-current		250,000	250,000
Total financial assets as trade and other receivables	17	<u>2,038,699</u>	<u>4,278,626</u>

Provision for Impairment of Receivables

Current trade receivables are generally on 30 days term. These receivables are assessed for recoverability and a provision for impairment is recognised when there is objective evidence that the individual trade receivable is impaired. There is no provision for impairment of receivables at 31 December 2015.

Note 7: Financial Assets

	<u>Note</u>	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Non-current			
Available for sale financial instruments			
Shares in listed securities - at fair value		11,422,798	9,630,871
Total financial assets	17	<u>11,422,798</u>	<u>9,630,871</u>

Available-for-sale financial assets comprise investments in the ordinary issued capital of various entities. There are fixed returns and fixed maturity dates attached to some of these investments.

Note 8: Other Assets

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Current		
Prepayments	84,551	88,220
Total other assets	<u>84,551</u>	<u>88,220</u>

Note 9: Property, Plant & Equipment

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Plant & equipment:		
Plant, equipment and fixtures at cost	15,235,461	14,807,909
Less accumulated depreciation	<u>(12,924,383)</u>	<u>(11,518,045)</u>
Total plant, equipment and fixtures	2,311,078	3,289,864
Property:		
Leasehold improvements at cost	11,975,464	11,584,517
Less accumulated amortisation	<u>(8,935,127)</u>	<u>(8,049,931)</u>
Total leasehold improvements	3,040,337	3,534,586
Motor vehicles:		
Motor vehicles at cost	53,929	53,928
Less accumulated depreciation	<u>(31,144)</u>	<u>(13,347)</u>
Total motor vehicles	22,785	40,581
Total property, plant & equipment	<u>5,374,200</u>	<u>6,865,031</u>

Movements in Carrying Amounts:

Plant & equipment:		
Balance at beginning of the year	3,289,864	4,011,475
Additions - OBI acquisition	116,048	-
Additions - purchases	311,504	702,922
Depreciation expense	<u>(1,406,338)</u>	<u>(1,424,533)</u>
Carrying amount at end of the year	2,311,078	3,289,864
Property:		
Balance at beginning of the year	3,534,586	3,812,930
Additions - OBI acquisition	381,474	-
Additions - purchases	9,473	511,482
Depreciation expense	<u>(885,195)</u>	<u>(789,826)</u>
Carrying amount at end of the year	3,040,338	3,534,586
Motor vehicles:		
Balance at beginning of the year	40,581	-
Additions	-	53,928
Depreciation expense	<u>(17,796)</u>	<u>(13,347)</u>
Carrying amount at end of the year	22,785	40,581
Total property, plant & equipment	<u>5,374,200</u>	<u>6,865,031</u>

Note 10: Trade and Other Payables

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Current		
Unsecured liabilities:		
Trade payables	1,759,638	1,611,455
Deferred income	952,521	882,950
Employee benefits (annual leave entitlements)	789,892	753,532
Total trade and other payables	<u>3,502,051</u>	<u>3,247,937</u>
Financial liabilities amortised at cost classified as trade and other payables:		
Trade and other payables:		
Total current	3,502,051	3,247,937
Total non-current	-	-
Less deferred income	(952,521)	(882,950)
Less annual leave entitlements	(789,892)	(753,532)
Total financial liabilities as trade and other payables	<u>17</u> <u>1,759,638</u>	<u>1,611,455</u>

Note 11: Provisions

	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Provision for employee entitlements:		
Opening balance at beginning of the year	1,552,280	1,446,386
Acquired provision - OBI	217,827	-
Additional provisions raised during the year	245,249	242,040
Amounts used	(271,201)	(136,146)
Balance at the end of the year	<u>1,744,155</u>	<u>1,552,280</u>
Analysis of total provisions:		
Current	1,658,409	1,463,558
Non-current	85,746	88,722
Total provision for employee entitlements	<u>1,744,155</u>	<u>1,552,280</u>

Provision for long-term employee entitlements:

A provision has been recognised for employee entitlements relating to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits has been included in Note 1(i) to this report.

Leave benefits:

The company's long service leave liability of \$1,744,155 represents a gross liability of \$1,760,343 offset by net present value reimbursement obligations of \$16,188 from National Health and Medical Research Council (NHMRC), applicable up to 31 December 2001. This payment will be receivable upon payment of long service leave by the company on behalf of eligible employees. NHMRC reimburse long service leave payments on a pro-

rata basis for the period of their grant support.

Note 12: Reserve

Financial assets reserve

The financial assets reserve records revaluation of increments and decrements (that do not represent impairment write-downs) that refer to financial assets that are classified as available-for-sale. The total reduction in the market value of the shares for 2015 is \$290,955, which is reflected in the financial accounts as a decrease in the financial asset reserve.

Note 13: Contingent Liabilities and Contingent assets

There are no contingent assets or liabilities to be disclosed in the financial report.

Note 14: Related party transactions

During 2015, DMP Asset Management Ltd managed part of the company's investment portfolio. The Chair of the company's board, Ms Brenda Shanahan, is a director of DMP Asset Management.

During 2015, an employee of the company worked as the personal assistant to the Executive Director, Professor Tom Kay and worked on a contract basis for Professor Tom Kay's wife.

Note 15: Funds held in trust

The \$138,280 represents funds transferred to the company in December 1998 to cover the value of accumulated annual and long service leave for the National Serology Reference Laboratory (NSRL) staff, who transferred to the company under the company's agreement with the Commonwealth of Australia. If at anytime the contractual agreement with the Commonwealth of Australia ceases, the funds will be allocated to the payment of NSRL staff leave entitlements.

Note 16: Key Management Personnel Compensation

The totals of remuneration paid to key management personnel of the company during the year are as follows:

	2015 (\$)	2014 (\$)
Key management personnel compensation	572,025	571,344

Note 17: Financial Risk Management

The company's financial instruments consist mainly of deposits with banks, local money market instruments, short-term investments, accounts receivable and payable, bills and leases.

The totals for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows:

	<u>Note</u>	<u>2015 (\$)</u>	<u>2014 (\$)</u>
Financial assets			
Cash and cash equivalents	5	10,955,053	6,635,128
Loans and receivables	6	2,038,699	4,278,626
Available for sale financial instruments			
Shares in listed securities - at fair value	7	11,422,798	9,630,871
Total financial assets		<u>24,416,550</u>	<u>20,544,625</u>
Financial liabilities			
Financial liabilities at amortised cost			
Trade and other payables	10	1,759,638	1,611,455
Total financial liabilities		<u>1,759,638</u>	<u>1,611,455</u>

Note 18: Fair Value Measurement

The following table provides the fair value measurement hierarchy of the company's assets.

	<u>Note</u>	<u>Fair value measurement using</u> <u>31 December 2015</u>		
		<u>Quoted</u> <u>prices in</u> <u>active</u> <u>markets</u> <u>(Level 1)</u> <u>(\$)</u>	<u>Significant</u> <u>observable</u> <u>inputs</u> <u>(Level 2)</u> <u>(\$)</u>	<u>Significant un-</u> <u>observable</u> <u>inputs</u> <u>(Level 3)</u> <u>(\$)</u>
Assets				
Shares in listed securities	7	11,422,798	-	-
Loan - SVH Imprest Advance	6	-	-	250,000
		<u>11,422,798</u>	<u>-</u>	<u>250,000</u>

Note 19: Segment Reporting

The company operates in the medical research sector where it undertakes basic and clinical research in Australia.

Note 20: Events after the reporting period

No matter or circumstances have arisen between the end of the financial year and the date of this report which have or may significantly affect the state of the operations or the state of the affairs of the company in subsequent years.

Note 21: Company Details

The registered office and principal place of business of the company is:

St. Vincent's Institute of Medical Research
9 Princes Street
Fitzroy, Vic 3065

Directors' Declaration

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 8 to 25 are in accordance with the Australian Charities and Not-for-Profits Commission Act 2012 and:
 - a) comply with Accounting Standards – Reduced Disclosure Requirements: and
 - b) give a true and fair view of the financial position as at 31 December 2015 and of the performance for the year ended on that date of the company:
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Director

BM Shanahan



Director

TWH Kay

Dated this 23rd day of March 2016, Melbourne, Australia

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH

Report on the Financial Report

We have audited the accompanying financial report of St. Vincent's Institute of Medical Research, which comprises the statement of financial position as at 31 December 2015, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Financial Report

The directors are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Reduced Disclosure Regime and the *Australian Charities and Not-for-Profits Commission Act 2012* and for such internal control as the directors determine is necessary to enable the preparation and fair presentation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

CHARTERED ACCOUNTANTS & ADVISORS

Melbourne Office
Level 20, 181 William Street
Melbourne VIC 3000

Hawthorn Office
Level 1, 465 Auburn Road
Hawthorn East VIC 3123

PO Box 185, Toorak VIC 3142
Telephone: +61 3 9824 8555
williambuck.com

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (CONT)

Auditor's Opinion

In our opinion the financial report of St. Vincent's Institute of Medical Research is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- a) Giving a true and fair view of the company's financial positions as at 31 December 2015 and of its performance for the year then ended on that date; and
- b) Complying with Australian Accounting Standards – Reduced Disclosure Requirements (including the Australian Accounting Interpretations) and the *Australian Charities and Not-for-Profits Commission Regulation 2013*.

Matters Relating to the Electronic Presentation of the Audited Financial Report

This auditor's report relates to the financial report of St. Vincent's Institute of Medical Research for the year ended 31 December 2015 included on St. Vincent's Institute of Medical Research web site. The company's directors are responsible for the integrity of the St. Vincent's Institute of Medical Research's web site. We have not been engaged to report on the integrity of the St. Vincent's Institute of Medical Research's web site. The auditor's report refers only to the financial report. It does not provide an opinion on any other information which may have been hyperlinked to/from these statements. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the audited financial report to confirm the information included in the audited financial report presented on this web site.



William Buck Audit (VIC) Pty Ltd
ABN 59 116 151 136



A.P. Marks
Director

Dated this 23rd day of March, 2016

CHARTERED ACCOUNTANTS & ADVISORS

Melbourne Office
Level 20, 181 William Street
Melbourne VIC 3000

Hawthorn Office
Level 1, 465 Auburn Road
Hawthorn East VIC 3123

PO Box 185, Toorak VIC 3142
Telephone: +61 3 9824 8555
williambuck.com

St Vincent's Institute

Postal: 41 Victoria Parade,
Fitzroy Victoria 3065
Location: 9 Princes Street,
Fitzroy Victoria 3065

Tel: 03 9288 2480
Fax: 03 9416 2676
Email: enquiries@svi.edu.au
Web: www.svi.edu.au
ABN: 52 004 705 640

